The treatment of scleroderma

F. M. Wigley, C. L. Boling

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

There is currently no perfect treatment for scleroderma. Most success is focused on organ-specific therapy. The current theory of pathogenesis suggests that potential targets of therapy are the autoimmune process, tissue fibrosis, inflammation and/or scleroderma vascular disease. This year, a controlled trial suggested that D-penicillamine was not effective in scleroderma. Relaxin, an insulin-like protein, shows promise for scleroderma skin disease when given by continuous subcutaneous infusion. Anti-cytokine therapy is being tested in animal models of fibrosis, but few clinical data are available. Intravenous or inhaled prostaglandins seem to improve pulmonary hypertension, a leading cause of mortality in scleroderma. Cyclophosphamide appears to arrest active alveolitis and to stabilize declining lung function. Aggressive therapy for severe disease with autologous bone marrow transplant is also under study. This article reviews the rationale for new therapy and several reported clinical trials.

Original languageEnglish (US)
Pages (from-to)276-292
Number of pages17
JournalCurrent Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs
Volume2
Issue number4
StatePublished - 2000

Fingerprint

Fibrosis
Therapeutics
Relaxin
Subcutaneous Infusions
Penicillamine
Vascular Diseases
Skin Diseases
Pulmonary Hypertension
Cyclophosphamide
Prostaglandins
Animal Models
Bone Marrow
Clinical Trials
Insulin
Cytokines
Inflammation
Transplants
Lung
Mortality
Proteins

Keywords

  • Antioxidants
  • Cytokines
  • Fibrosis
  • Immune system
  • Inflammation
  • Prostaglandins
  • Raynaud's
  • Scleroderma
  • Vascular diseases

ASJC Scopus subject areas

  • Pharmacology
  • Immunology

Cite this

The treatment of scleroderma. / Wigley, F. M.; Boling, C. L.

In: Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs, Vol. 2, No. 4, 2000, p. 276-292.

Research output: Contribution to journalArticle

@article{88aae7c35d0f40d88582dc42880fc0db,
title = "The treatment of scleroderma",
abstract = "There is currently no perfect treatment for scleroderma. Most success is focused on organ-specific therapy. The current theory of pathogenesis suggests that potential targets of therapy are the autoimmune process, tissue fibrosis, inflammation and/or scleroderma vascular disease. This year, a controlled trial suggested that D-penicillamine was not effective in scleroderma. Relaxin, an insulin-like protein, shows promise for scleroderma skin disease when given by continuous subcutaneous infusion. Anti-cytokine therapy is being tested in animal models of fibrosis, but few clinical data are available. Intravenous or inhaled prostaglandins seem to improve pulmonary hypertension, a leading cause of mortality in scleroderma. Cyclophosphamide appears to arrest active alveolitis and to stabilize declining lung function. Aggressive therapy for severe disease with autologous bone marrow transplant is also under study. This article reviews the rationale for new therapy and several reported clinical trials.",
keywords = "Antioxidants, Cytokines, Fibrosis, Immune system, Inflammation, Prostaglandins, Raynaud's, Scleroderma, Vascular diseases",
author = "Wigley, {F. M.} and Boling, {C. L.}",
year = "2000",
language = "English (US)",
volume = "2",
pages = "276--292",
journal = "Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs",
issn = "1464-8474",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - The treatment of scleroderma

AU - Wigley, F. M.

AU - Boling, C. L.

PY - 2000

Y1 - 2000

N2 - There is currently no perfect treatment for scleroderma. Most success is focused on organ-specific therapy. The current theory of pathogenesis suggests that potential targets of therapy are the autoimmune process, tissue fibrosis, inflammation and/or scleroderma vascular disease. This year, a controlled trial suggested that D-penicillamine was not effective in scleroderma. Relaxin, an insulin-like protein, shows promise for scleroderma skin disease when given by continuous subcutaneous infusion. Anti-cytokine therapy is being tested in animal models of fibrosis, but few clinical data are available. Intravenous or inhaled prostaglandins seem to improve pulmonary hypertension, a leading cause of mortality in scleroderma. Cyclophosphamide appears to arrest active alveolitis and to stabilize declining lung function. Aggressive therapy for severe disease with autologous bone marrow transplant is also under study. This article reviews the rationale for new therapy and several reported clinical trials.

AB - There is currently no perfect treatment for scleroderma. Most success is focused on organ-specific therapy. The current theory of pathogenesis suggests that potential targets of therapy are the autoimmune process, tissue fibrosis, inflammation and/or scleroderma vascular disease. This year, a controlled trial suggested that D-penicillamine was not effective in scleroderma. Relaxin, an insulin-like protein, shows promise for scleroderma skin disease when given by continuous subcutaneous infusion. Anti-cytokine therapy is being tested in animal models of fibrosis, but few clinical data are available. Intravenous or inhaled prostaglandins seem to improve pulmonary hypertension, a leading cause of mortality in scleroderma. Cyclophosphamide appears to arrest active alveolitis and to stabilize declining lung function. Aggressive therapy for severe disease with autologous bone marrow transplant is also under study. This article reviews the rationale for new therapy and several reported clinical trials.

KW - Antioxidants

KW - Cytokines

KW - Fibrosis

KW - Immune system

KW - Inflammation

KW - Prostaglandins

KW - Raynaud's

KW - Scleroderma

KW - Vascular diseases

UR - http://www.scopus.com/inward/record.url?scp=0033847550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033847550&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033847550

VL - 2

SP - 276

EP - 292

JO - Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs

JF - Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs

SN - 1464-8474

IS - 4

ER -